UC Davis Health Ventures, operating under the Innovation and Economic Development Office (IEDO) at the University of California, Davis, has recently announced its first investment from the Investing in the Future of Medicine (IFM) Fund in Delix Therapeutics. Delix, a spinout from UC Davis, is dedicated to developing non-hallucinogenic neuroplastogens for major depressive disorder (MDD) and other severe neuropsychiatric and neurodegenerative conditions.
Professor David E. Olson’s research at UC Davis laid the foundation for Delix’s innovative approach, focusing on separating the therapeutic benefits of psychedelics from their hallucinogenic effects. This effort led to the creation of next-generation non-hallucinogenic compounds designed to enhance neuroplasticity. Delix’s lead candidate, DLX-001 (Zalsupindole), is currently undergoing clinical trials and has shown promising results in Phase 1a for safety and tolerability, as well as demonstrating engagement with the central nervous system through a novel biomarker relevant to neuroplasticity. Additionally, a Phase 1b study in MDD patients illustrated rapid, sustained, and significant reductions in depressive symptoms with DLX-001.
The prevalence of MDD, impacting approximately 15 to 20% of individuals during their lifetime, underscores the critical need for innovative therapies. Delix’s focus on scalable treatments that improve neuroplasticity without causing hallucinogenic effects could significantly broaden access to transformative therapies, particularly benefiting patients who do not respond to current interventions. For individuals who have struggled with multiple therapies unsuccessfully, Delix’s compounds offer a new avenue for treatment with rapid and robust effects within days.
Mark Rus, CEO of Delix Therapeutics, emphasized the essential role of UC Davis research in the development of their therapeutic platform and expressed gratitude for the university’s ongoing support. Partnerships with a shared vision for addressing MDD through non-hallucinogenic neuroplastogens are crucial as Delix advances its pipeline of neuroplastogens, including Zalsupindole (DLX-001).
Investments like the one made through the IFM Fund not only diversify UC Davis Health’s revenue streams but also support companies like Delix that are making a clinical impact. By backing innovative ventures such as Delix, UC Davis Health aims to enhance its financial sustainability while facilitating the delivery of transformative therapies to patients in need.
The establishment of the IFM Fund earlier this year aligns with UC Davis’ commitment to fostering innovation and economic development. This initiative complements existing programs that support researchers and students, creating a comprehensive pathway for advancing translational research and facilitating investments in collaboration with external partners.
Through a collaborative effort with UC Investments, the investment in Delix demonstrates a model that combines clinical expertise with institutional capital to drive impactful ventures. By leveraging UC’s vast resources and intellectual property, Delix Therapeutics is poised to address critical unmet needs in neuropsychiatric and neurological disorders.
The journey of Professor David E. Olson and Delix exemplifies the success of UC Davis’ innovation ecosystem in translating research into tangible solutions. Early support received through programs like the STAIR Grant and START program, managed by IEDO’s Venture Catalyst team, played a crucial role in propelling Olson’s research from the laboratory to a company that has attracted substantial venture support. The IFM Fund’s investment represents a significant milestone in this trajectory.
The IFM Fund, managed by UC Davis Health Ventures, plays a pivotal role in accelerating the translation of impactful innovations and supporting external companies aligned with addressing major health challenges. Operating alongside the Health Venture Studio at Aggie Square, the IFM Fund aims to de-risk UC Davis discoveries to facilitate their adoption in clinical settings and markets.
Delix Therapeutics, as a clinical-stage neuroscience company, is committed to leveraging novel neuroplasticity-promoting therapeutics to enhance the treatment of challenging neuropsychiatric and neurological disorders. Through its Neuroplastogen Platform, Delix is pioneering fast-acting outpatient pharmacotherapies that aim to address unmet needs and improve the treatment landscape for patients and healthcare providers.
In conclusion, UC Davis Health Ventures’ investment in Delix Therapeutics marks a significant step in advancing innovative solutions for MDD and other neurological conditions. The collaboration between academia, industry, and investors underscores the importance of translating research into impactful therapies that can enhance patient outcomes and address critical unmet needs in healthcare.
Key Takeaways:
– UC Davis Health Ventures’ IFM Fund investment in Delix Therapeutics supports the development of non-hallucinogenic neuroplastogens for MDD and other neuropsychiatric conditions.
– Delix’s lead candidate, DLX-001 (Zalsupindole), has shown promise in clinical trials for safety, tolerability, and efficacy in reducing depressive symptoms.
– The IFM Fund aims to accelerate the translation of high-impact innovations and invest in companies addressing major health needs, fostering collaboration between academia and industry.
– Delix Therapeutics’ focus on neuroplasticity-promoting therapeutics represents a novel approach to treating challenging neuropsychiatric and neurological disorders.
Tags: clinical trials
Read more on ucdavis.edu